Type of Event: Q1FY27 Earnings Call (Results Conference Call)

Date and Time: Wednesday, August 12, 2026 at 10:00 AM IST

Purpose: To discuss the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1FY27). The call will also discuss the company's business strategy and outlook post the declaration of results.

Timing Relative to Earnings: The meeting is scheduled after the earnings announcement, as it is described as a post-results discussion.

Management Participants:

  • Mr. Vikram Vuppala – Chairman & Managing Director
  • Mr. Kamal Shah – Co-Founder
  • Mr. Rohit Singh – Group CEO
  • Mr. Prashant Goenka – Group Chief Financial Officer

Availability of Materials: The intimation disclosure is available on the company website at www.nephroplus.com. The document mentions an attachment (enclosure) of the invitation but does not specify if a presentation deck, transcript, or recording will be made available post-call.

UPSI Compliance: The company has explicitly stated that "Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions."

Financial Data Disclosure: No financial figures, guidance, or strategic themes were disclosed in this announcement.

Additional Notes Section

Attachments: The submission includes an enclosure (a/a), which is the detailed investor invite from IIFL Securities.

Logistical Details: The invite from IIFL Securities provides comprehensive dial-in information:

  • Pre-registration: Diamond Pass Registration link is provided.
  • India Primary: +91 22 6280 1259 / +91 22 7115 8160
  • Toll-free numbers: USA: 1-866 746 2133 | UK: 0-808 101 1573 | Singapore: 800-101 2045 | Hong Kong: 800-964 448
  • International Time Zones: HK/Singapore – 12:30 pm, UK – 5:30 am, USA – 12:30 am ET

IIFL Contacts: The organizing brokerage firm IIFL Capital Services Limited provided contacts for further information: Naman Bagrecha, Rahul Jeewani, Aman Goyal, and Vighnesh Indure.

Regulatory Reference: The intimation is made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The reference number for the filing is NEPHROPLUS/SE/066, dated July 24, 2026, and signed by Company Secretary & Head Legal Kishore Kathri (ICSI M. No. F9895).